Skip to main
GLUE

GLUE Stock Forecast & Price Target

GLUE Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Monte Rosa Therapeutics's stock outlook is bolstered by an increase in its enterprise value to approximately $3.28 billion, driven by advancements in its pipeline and solid cash projections for year-end 2026, now expected to be $505 million. The valuation for the NEK7 MGD MRT-8102 has risen significantly to $1.16 billion, highlighting positive interim Phase I data that enhances investor confidence in the company's therapeutic developments. Furthermore, the expansion of the NEK7 program to next-generation MGDs with improved properties, particularly for central nervous system penetration, showcases Monte Rosa's commitment to addressing unmet medical needs and fostering innovation in the biotechnology sector.

Bears say

Monte Rosa Therapeutics Inc. faces several financial and operational challenges that contribute to a negative outlook on its stock. The company's reliance on strategic partnerships, specifically with Roche and Novartis, may be at risk, potentially leading to future difficulties in securing new collaborations that are essential for funding and advancing its pipeline of molecular glue degraders (MGDs). Additionally, significant risks relating to research and development, regulatory approvals, competition, and management execution pose threats to the company's valuation and overall business stability.

GLUE has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Monte Rosa Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Monte Rosa Therapeutics (GLUE) Forecast

Analysts have given GLUE a Buy based on their latest research and market trends.

According to 3 analysts, GLUE has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Monte Rosa Therapeutics (GLUE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.